Joshua James
Overview
Energetic and committed, Joshua James helps clients strengthen and enforce their intellectual property rights. Josh’s practice focuses on patent litigation, particularly Hatch-Waxman pharmaceutical litigation in federal courts and inter partes review proceedings before the Patent Trial and Appeal Board.
Career & Education
- Illinois Institute of Technology (IIT)
Research Experience for Undergraduates, June 2010–August 2011
Inter-Professional Research Opportunity (IPRO), January 2011–May 2011
Biomedical Engineering Senior Design, August 2009–May 2010
Research Experience for Undergraduates, June 2009–August 2009 - Rehabilitation Institute of Chicago
Research Experience for Undergraduates, June 2008–August 2008
- Illinois Institute of Technology (IIT)
- Illinois Institute of Technology, B.S., Summa cum Laude, chemical engineering, 2011
- Illinois Institute of Technology, B.S., Summa cum Laude, biomedical engineering, 2011
- Indiana University - Bloomington, Maurer School of Law, J.D., cum Laude, 2014
- Illinois
- U.S. Patent and Trademark Office (USPTO)
- U.S. District Court for the Northern District of Illinois
- U.S. Court of Appeals for the Federal Circuit
- Supreme Court of the United States
Professional Activities and Memberships
- PTAB Bar Association, 2016–present
- American Intellectual Property Law Association, 2011–present
- Chicago Bar Association, 2015–present
- Indiana Law Journal, Board Member, 2013–2014
- Intellectual Property Association, 2011–2014
- Phi Alpha Delta, Clerk, 2013
Joshua 's Insights
Client Alert | 4 min read | 05.05.26
As prescription drug prices continue to soar in the United States, the Supreme Court recently heard the highly anticipated oral arguments in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., the first patent case at the Court since 2023. While the Justices did not seem motivated to make significant changes to the current standards for induced patent infringement, the stakes are high for brand and generic pharmaceutical companies, as each side continues to wrestle with the main dilemma that this case raises: What is the right balance between marketing skinny labels to engage in lawful generic competition and avoiding induced infringement liability?
Client Alert | 3 min read | 12.24.24
Only Drugs Allowed: Federal Circuit Affirms Order To Delist Device Patents From the Orange Book
Firm News | 4 min read | 08.15.24
Client Alert | 2 min read | 06.27.24
Recognition
- Best Lawyers: Ones to Watch in America, Illinois Commercial Litigation, 2025–2026
- Illinois Institute of Technology: Biomedical Engineering Distinguished Undergraduate Alumnus, 2017
- Indiana University Maurer School of Law: Dean’s Honors, Fall 2011, Spring/Fall 2013
- Illinois Institute of Technology: Camras Scholarship, Dean’s List, and Tau Beta Pi, 2007–2011
Joshua 's Insights
Client Alert | 4 min read | 05.05.26
As prescription drug prices continue to soar in the United States, the Supreme Court recently heard the highly anticipated oral arguments in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., the first patent case at the Court since 2023. While the Justices did not seem motivated to make significant changes to the current standards for induced patent infringement, the stakes are high for brand and generic pharmaceutical companies, as each side continues to wrestle with the main dilemma that this case raises: What is the right balance between marketing skinny labels to engage in lawful generic competition and avoiding induced infringement liability?
Client Alert | 3 min read | 12.24.24
Only Drugs Allowed: Federal Circuit Affirms Order To Delist Device Patents From the Orange Book
Firm News | 4 min read | 08.15.24
Client Alert | 2 min read | 06.27.24
Insights
Federal Circuit Denies En Banc Rehearing for Hepatitis Drug Patent Ruling
|10.27.14
Joshua 's Insights
Client Alert | 4 min read | 05.05.26
As prescription drug prices continue to soar in the United States, the Supreme Court recently heard the highly anticipated oral arguments in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., the first patent case at the Court since 2023. While the Justices did not seem motivated to make significant changes to the current standards for induced patent infringement, the stakes are high for brand and generic pharmaceutical companies, as each side continues to wrestle with the main dilemma that this case raises: What is the right balance between marketing skinny labels to engage in lawful generic competition and avoiding induced infringement liability?
Client Alert | 3 min read | 12.24.24
Only Drugs Allowed: Federal Circuit Affirms Order To Delist Device Patents From the Orange Book
Firm News | 4 min read | 08.15.24
Client Alert | 2 min read | 06.27.24
